866-997-4948(US-Canada Toll Free)

Dyslipidemia Pipeline Assessment and Market Forecasts to 2016

Published By :

GlobalData

Published Date : Jun 2010

Category :

Therapeutic Area

No. of Pages : 84 Pages


GlobalData, the industry analysis specialist, has released a new report, Dyslipidemia Pipeline Assessment and Market Forecasts to 2016. The report is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dyslipidemia sector. GlobalData estimated the global dyslipidemia market to be valued at $34.4 billion in 2009. 

It is expected to decline at a compound annual growth rate (CAGR) of approximately 3.7% from $34.4 billion in 2009 to $26.3 billion by 2016. Although the cardiovascular market expanded considerably between 2004 and 2008, growth in the seven major markets is expected to slow down from 2012. The decline is sales during this period would be due to the expiry of leading brands patents. Pfizers Lipitor, which is a major blockbuster in the dyslipidemia market, is set to expire in 2011 along with Trilipixs. Zetia, Vyotrin, Simcor, Lescol, Livalo and Lovaza are set to expire between 2012 and 2014. Growth in the market is being driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages such as once-daily administration and combinational therapies. 

Cetriad, belonging to AstraZeneca and Abbott Laboratories, has been filed with the US FDA and is currently the most anticipated drug. GlobalData found that there are over 98 molecules in various stages of the pipeline. Cetriad, Trilipix in combination with atorvastatin, Trilipix in combination with simvastatin, RG1658, MK-0524A, Caduet, GFT-505, AEGR-733, AMR-101 and MK-859 are some of the promising molecules in late stage dyslipidemia pipeline. These molecules differ in their targets and mechanisms of action from the existing therapies. Most of these molecules are combination products of already marketed drugs. Novelty exists in terms of using two different drugs in combination in order to provide better efficacy. Some of the drugs in the late stage pipeline such as GFT 505 and MK-0524A are completely novel to the dyslipidemia market. Though the dyslipidemia pipeline is strong in terms of first-in-class and me-too products, only a small number of products are expected to enter the market before 2016. Inspite of its strong pipeline, the dyslipidemia market is declining due to the expiries of the patents of its major blockbuster drugs. GlobalData has found that the available treatment options have been moderately successful in meeting the market demand. The current therapeutics compete to provide rapid decreases in LDL-C (low density lipoprotein-cholesterol), TG (tryglycerides), TC (total cholesterol) levels and increases in HDL-C (high density lipoprotein-cholesterol) levels and improve patients overall quality of life. 

The treatments approved for the treatment of dyslipidemia also minimize the risk of cardiovascular disorders. Overall, there is strong competition among the currently marketed products for symptomatic treatment of the disease. Although the current dyslipidemia treatments are only symptomatic, they treat patients effectively. Hence the market for dyslipidemia is strong. However, safety remains a concern as antidyslipidemic drugs are associated with serious adverse effects such as myopathy or rhabdomylosis, liver disease and increased liver enzymes. There is significant potential for any new entrant that can cater to these unmet needs. A product with disease modifying mechanisms, a better safety profile and good efficacy is sure to achieve blockbuster drug status. Thus, a strong opportunity exists for any drug that offers better efficacy and safety than is provided by the current players.

Scope

The scope of the report includes: 

  • Annualized global dyslipidemia market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. 
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. 
  • Analysis of the current and future market competition in the global dyslipidemia market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with dyslipidemia
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to: 

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market. 
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global dyslipidemia market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global dyslipidemia market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Global Dyslipidemia Market: Market Characterization 6
2.1 Overview 6
2.2 Dyslipidemia Market Size 6
2.3 Dyslipidemia Market Forecast and CAGR 6
2.4 Drivers and Barriers for Dyslipidemia Market 7
2.4.1 Drivers for Dyslipidemia Market 7
2.4.2 Barriers for Dyslipidemia Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 11

3 Dyslipidemia Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in Dyslipidemia Market 13
3.3.1 Lipitor (atorvastatin calcium) 13
3.3.2 Vyotrin (ezetimibe/simvastatin) 14
3.3.3 Zetia (ezetimibe) 15
3.3.4 Trilipix (fenofibric acid) 17
3.3.5 Simcor (simvastatin/niacin extended release tablets) 18
3.3.6 Lescol (fluvastatin sodium) 19
3.3.7 Livalo (pitavastatin calcium) 21
3.3.8 Lovaza (omega-3-acid ethyl esters) 22
3.4 Key Takeaway 26

4 Dyslipidemia Market: Pipeline Assessment 27
4.1 Overview 27
4.2 Strategic Pipeline Assessment 27
4.2.1 Technology Trends Analytic Framework 27
4.3 Dyslipidemia Therapeutics Promising Drugs under Clinical Development 29
4.4 Molecule Profile for Promising Drugs for Dyslipidemia Under Clinical Development 33
4.4.1 Cetriad (rosuvastatin/fenofibric acid, ABT-335) 33
4.4.2 ABT335 (SLV348, Trilipix) + simvastatin or atorvastatin 34
4.4.3 RG1658 (Dalcetrapib, JTT-705, RO4607381) 35
4.4.4 MK-0524A (Cordaptive, niacin + laropiprant) 36
4.4.5 Caduet (amlodipine + atorvastatin) 38
4.4.6 GFT505 39
4.4.7 AEGR-733 (lopitamide, BMS-201038) 40
4.4.8 AMR101 (LAX-101, Miraxion) 41
4.4.9 MK-0859 (anacetripib) 42
4.5 Dyslipidemia Therapeutics Market Clinical Pipeline by Mechanism of Action 44
4.6 Dyslipidemia Pipeline Pipeline by Clinical Phases of Development 45
4.6.1 Dyslipidemia Therapeutics Phase III Clinical Pipeline 46
4.6.2 Dyslipidemia Therapeutics Phase II Clinical Pipeline 47
4.6.3 Dyslipidemia Therapeutics Phase I Clinical Pipeline 49
4.6.4 DyslipidemiaTherapeutics Preclinical Pipeline 50
4.6.5 DyslipidemiaTherapeutics Discovery Pipeline 50
4.7 Discontinued / Suspended Drug for Dyslipidemia 51
4.8 Key Takeaway 53

5 Dyslipidemia Market: Implications for Future Market Competition 54

6 Dyslipidemia Market: Future Players in the Dyslipidemia Market 56
6.1 Introduction 56
6.2 AstraZeneca PLC 56
6.2.1 Overview 56
6.2.2 Cardiovascular Disease Portfolio 57
6.2.3 Dyslipidemia Product Portfolio 57
6.3 Abbott Laboratories 59
6.3.1 Overview 59
6.3.2 Cardiovascular Disease Portfolio 60
6.3.3 Dyslipidemia Product Portfolio 60
6.4 Merck & Co. 62
6.4.1 Overview 62
6.4.2 Cardiovascular Disease Portfolio 63
6.4.3 Cardiovascular Product Portfolio 63
6.5 GenFit 66
6.5.1 Overview 66
6.5.2 Cardiovascular Disease Portfolio 67
6.5.3 Cardiovascular Product Portfolio 67
6.6 Aegerion Pharmaceuticals, Inc. 68
6.6.1 Overview 68
6.6.2 Cardiovascular Disease Portfolio 68
6.6.3 Dyslipidemia Product Portfolio 68
6.7 Amarin Corporation Plc 70
6.7.1 Overview 70
6.7.2 Cardiovascular Disease Portfolio 70
6.7.3 Dyslipidemia Product Portfolio 71
6.8 Pfizer Inc. 72
6.8.1 Overview 72
6.8.2 Dyslipidemia Product Portfolio 73
6.9 Roche 74
6.9.1 Overview 74
6.9.2 Dyslipidemia Product Portfolio 75

7 Dyslipidemia Market: Appendix 77
7.1 Market Definitions 77
7.2 Abbreviations 77
7.3 Research Methodology 79
7.3.1 Coverage 79
7.3.2 Secondary Research 80
7.3.3 Forecasting 80
7.3.4 Primary Research 83
7.3.5 Expert Panels 83
7.4 Contact Us 83
7.5 Disclaimer 83
7.6 Sources 84

List of Table

 
Table 1: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2001-2009 6
Table 2: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2009-2016 7
Table 3: Major Marketed Products Comparison in the Dyslipidemia Market, 2010 24
Table 4: Dyslipidemia Therapeutics Most Promising Drugs Under Clinical Development, 2010 29
Table 5: Dyslipidemia Therapeutics Phase III Clinical Pipeline, 2010 46
Table 6: Dyslipidemia Therapeutics Phase II Clinical Pipeline, 2010 47
Table 7: Dyslipidemia Therapeutics Phase I Clinical Pipeline, 2010 49
Table 8: Dyslipidemia Therapeutics Preclinical Pipeline, 2010 50
Table 9: Dyslipidemia Therapeutics Discovery Pipeline, 2010 50
Table 10: List of Discontinued Drugs for Dyslipidemia, 2010 51
Table 11: AstraZeneca PLCCardiovascular Pipeline Products, 2010 57
Table 12: Abbott LaboratoriesCardiovascular Pipeline Products, 2010 60
Table 13: Merck & Co. Cardiovascular Disease Pipeline Products, 2010 63
Table 14: GenFit -Cardiovascular Disease Pipeline Products, 2010 67
Table 15: Aegerion Pharmaceuticals, Inc.- Cardiovascular Disease Pipeline Products, 2010 68
Table 16: Amarin Corporation Plc. Cardiovascular Disease Pipeline Products, 2010 70
Table 17: Pfizer Inc. Cardiovascular Disease Pipeline Products, 2010 73
Table 18: Roche Cardiovascular Disease Pipeline Products, 2010 75

List of Chart

 
Figure 1: Global Dyslipidemia Therapeutics Market, Revenue ($bn), 20012009 6
Figure 2: Global Dyslipidemia Market Revenue ($bn), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Dyslipidemia Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Dyslipidemia, 2010 13
Figure 5: Technology Trends Analytic Framework of the Dyslipidemia Pipeline, 2010 28
Figure 6: Technology Trends Analytic Framework of the Dyslipidemia Pipeline Description, 2010 28
Figure 7: Dyslipidemia Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 44
Figure 8: Dyslipidemia Pipeline by Phase of Clinical Development, 2010 45
Figure 9: Implications for Future Market Competition in the Dyslipidemia Market, 2010 54
Figure 10: Dyslipidemia Therapeutics Market Clinical Pipeline by Company, 2010 56
Figure 11: GlobalData Methodology, 2010 79
Figure 12: GlobalData Market Forecasting Model 82

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *